Parts of healthcare are doing very well: equipment, disposables, more surgical procedures, managed care. Does this translate into stronger earnings and growth even during an economic contraction?
She picked it to start the year, but it hasn't performed well in the first six months. Healthcare has lagged this year, but when the VIX is this low, you want to hold defence.
She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.
She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.
Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.
Health Care Select Sector SPDR Fund is a American stock, trading under the symbol XLV-N on the NYSE Arca (XLV). It is usually referred to as AMEX:XLV or XLV-N
In the last year, 5 stock analysts published opinions about XLV-N. 5 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Health Care Select Sector SPDR Fund.
Health Care Select Sector SPDR Fund was recommended as a Top Pick by on . Read the latest stock experts ratings for Health Care Select Sector SPDR Fund.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered Health Care Select Sector SPDR Fund In the last year. It is a trending stock that is worth watching.
On 2023-10-02, Health Care Select Sector SPDR Fund (XLV-N) stock closed at a price of $128.595.
The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters.